22.88USD+1.67%Mkt Cap: 2.51B USDP/E: —Last update: 2026-05-26
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.51B USD
Enterprise Value2.14B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-183.79M USD
Revenue/Share—
Last Price22.88 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees105
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.33
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B6.73
EPS (TTM)-2.50
EPS (Forward)-1.58
52W Range
6.34583% of range26.25
52W High26.25 USD
52W Low6.345 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.30%
ROA-41.76%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-131.56M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.82%
Net Debt-332.65M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.12
Current Ratio4.69
Quick Ratio4.60
Book Value/Sh3.364 USD
Cash/Share3.424 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateAug 29, 2022
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)39.47 USD
Target Range25.00 USD – 70.00 USD
# Analysts15
Ownership
Shares Out.109.07M
Float108.06M
Insiders0.95%
Institutions74.54%
Short Interest
Short Ratio4.6d
Short % Float8.65%
Short % Out.8.58%
Shares Short9.36M
Short (prev mo.)15.13M
Technical
SMA 5020.77 (+10.1%)
SMA 20014.96 (+52.9%)
Beta2.38
S&P 52W Chg28.31%
Avg Vol (30d)1.78M
Avg Vol (10d)1.53M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—